Mary M. Rozenman, See Remarks at Aimmune Therapeutics, Inc. (AIMT), sold 60,610 shares at $38.80 ($2.4M) on 2017-12-26, disclosed to the SEC on 2017-12-28.
Open-market sale of $2.4M AIMT by See Remarks. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.73 | 6,400 | $248K | 10.5% |
| 2 | $38.80 | 4,310 | $167K | 7.1% |
| 3 | $38.82 | 11,000 | $427K | 18.1% |
| 4 | $38.82 | 10,700 | $415K | 17.6% |
| 5 | $38.83 | 11,000 | $427K | 18.1% |
| 6 | $38.83 | 8,800 |
| $342K |
| 14.5% |
| 7 | $39.15 | 3,600 | $141K | 6.0% |
| 8 | $39.23 | 1,500 | $59K | 2.5% |
| 9 | $39.23 | 1,800 | $71K | 3.0% |
| 10 | $39.25 | 1,500 | $59K | 2.5% |
| Total | $38.86 avg | 60,610 | $2.4M | 100% |
| Filing → |
| AIMT | SELL | 2018-01-04 | $489K | — | Filing → |
| AIMT | SELL | 2017-12-28 | $381K | — | Filing → |
| AIMT | SELL | 2017-12-28 | $2.2M | — | Filing → |